CNTB earnings analysis
What we found in CNTB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Connect Biopharma delivered a substantial revenue increase to $2.768 million, versus $48,000 in the prior-year quarter and $169,000 in the prior quarter, while diluted EPS improved sequentially to $(0.27) but remained worse year over year than $(0.23). The key operating catalyst is completion of enrollment in the 160-participant asthma and 159-participant COPD Phase 2 studies, with topline data expected in September 2026. However, the $17.284 million net loss and $16.273 million of R&D expense highlight continued high cash burn; management expects the $31.5 million cash balance to fund operations for at least one year. The 10-Q states that there were no material changes to the risk factors in the 2025 Annual Report and provides no numeric financial guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Increased Sharply
- Second-quarter revenue was $2.768 million, up from $48,000 in the prior-year quarter and $169,000 in the prior quarter, reflecting a significant milestone-related increase.
- Sequential EPS Improvement
- Diluted EPS was $(0.27), improving from $(0.34) in the prior quarter but worsening from $(0.23) in the prior-year quarter.
- Seabreeze STAT Enrollment Complete
- Enrollment was completed in the 160-participant asthma and 159-participant COPD Phase 2 Seabreeze STAT studies, with topline data expected in September 2026.
- At Least One Year of Cash Runway
- Management stated that the $31.5 million cash balance is expected to fund operations for at least one year from the release date.
- Controls Deemed Effective
- As of June 30, 2026, management concluded that disclosure controls and procedures were effective at the reasonable-assurance level.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Wider Net Loss
- Net loss increased to $17.284 million, indicating substantial ongoing cash consumption despite the $2.768 million revenue milestone in the quarter.
- Elevated Clinical Spending
- Research and development expense rose to $16.273 million as the company completed enrollment in two Phase 2 studies, increasing near-term spending ahead of the September 2026 data readout.
- Potential Insider-Share Supply
- The company has no material legal proceedings, but two executives adopted trading arrangements covering sales of up to 400,000 and 77,591 ordinary shares, respectively, during the quarter.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.27
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects topline results from the 160-participant asthma and 159-participant COPD Phase 2 Seabreeze STAT studies in September 2026 and expects the $31.5 million cash balance to fund operations for at least one year from the release date.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- Connect Biopharma reported minimal license revenue of $0.2 million for Q4 2026, a decline from $0.0 million in the prior year, with an EPS loss slightly improving from -0.27 to -0.30. The company increased its cash…
- 10-K · March 31, 2026
- Connect Biopharma is a clinical-stage company focused on rademikibart, an IL-4Rα monoclonal antibody targeting acute exacerbations of asthma and COPD; it initiated two parallel Phase 2 trials in May 2025 and expects…
- 10-Q · November 12, 2025
- Connect Biopharma reported Q3 license revenue of $16,000 and a GAAP net loss of $17.2 million (EPS $(0.31)), driven by higher R&D spend. Cash and short-term investments totaled $54.8 million as of September 30, 2025 and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CNTB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever